Under the purchase and sale agreement, VuCOMP will transfer its breast density technology and associated service contracts to iCAD. VuCOMP will continue to sell the breast density software, however, and also retain its CAD platform, according to the vendor. The companies will work together to transition service and support for existing M-Vu Breast Density customers over to iCAD, VuCOMP said. Financial terms of the deal were not disclosed.
The sale of M-Vu Breast Density technology will allow VuCOMP to focus its resources on developing CAD for breast tomosynthesis, President and Chief Technology Officer Jim Pike said in a statement. The firm has filed its premarket approval application for the breast tomosynthesis CAD software with the U.S. Food and Drug Administration and expects to launch the product by the fourth quarter of this year.
Copyright © 2015 AuntMinnie.com